Zenas BioPharma is a cross-border (China-USA based) biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in need.

Zenas is rapidly advancing a deep portfolio of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases.

Did you know?

Zenas (Greek) meaning: giving, godly giving, the gift of Zeus
泽纳 (“Zé Nà”) meaning: beneficence, favor, kindness; bounty; to accept, to hand in, water flowing together

Leadership

Lonnie Moulder, Founder & Executive Chair

Mr. Moulder, Founder of Zenas BioPharma, serves as our Executive Chair and is the Managing Member of Tellus BioVentures, LLC, an early-stage life sciences investment fund. Prior to establishing Tellus BioVentures, he cofounded TESARO (a fully-integrated Boston based oncology-focused biopharmaceutical company) and served as CEO and Director until its acquisition by GlaxoSmithKline in January 2019. Mr. Moulder previously served as President and CEO of Abraxis BioScience. Prior to Abraxis he served as Vice Chairman of Eisai Corporation of North America following Eisai’s acquisition of MGI PHARMA, where he served as President and CEO. This followed him serving as a member of the founding management team of a venture-stage biotech company. Mr. Moulder began as a clinical pharmacist followed by a 17-year career at predecessor companies of Sanofi, beginning with Marion Laboratories.

Mr. Moulder is a Temple University Trustee and Chair of the Trustee Committee for Research. He is a Council Member for both the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation. Mr. Moulder serves on the Board of Directors for Zai Lab, Helsinn Group and Trevena and for the Tellus BioVentures portfolio companies: Aegle Therapeutics, Dianthus Therapeutics, Interius BioTherapeutics and TamuroBio. He received a Pharmacy degree from Temple University and an MBA from The University of Chicago Booth School of Business.

Hua Mu, MD, Ph.D., President and Chief Executive Officer, Acting Chief Medical Officer

Dr. Hua Mu serves as President and Chief Executive Officer and Acting Chief Medical Officer at Zenas. Prior to joining Zenas, Dr. Mu was the co-founder of Overland Pharmaceuticals and served as Interim CEO and CMO, while also serving as Venture Partner at Hillhouse Capital. Prior to Overland, Dr. Mu served as CSO and President of R&D and later CMO of Simcere Pharmaceutical Group and President of Simcere of America Inc. Before Simcere, he was SVP and Global Head of Product Development Service and Partnership at WuXi AppTec. Prior to WuXi, he was EVP and CMO at Hutchison MediPharma in China. He previously held Medical Director and Head of Medical Affairs positions at several global pharmaceutical companies in the US, including Roche, Abraxis BioScience (Celgene/BMS), Biogen, and Genentech. With extensive experience in building and leading R&D organizations and international collaborations, Dr. Mu has a proven track record of successful development and approval of new drugs in China and around the globe. He participated in and led the development of more than 20 innovative drug candidates in multiple therapeutic areas, including three drugs approved in the US and global market, four in China, and an NDA currently under priority review in China.

Dr. Mu conducted translational and clinical research at the University of California, San Francisco and at the University of Washington Medical School before joining industry in 1999. He received his PhD in Genetic Epidemiology from the University of California at Berkeley and completed his post-doctorate training at University of California at San Francisco School of Medicine and University of Washington Medical School. Dr. Mu received his MD degree from West China University of Medical Sciences.

Joe Farmer, Chief Business and Administrative Officer

Mr. Farmer is the Chief Business and Administrative Officer of Zenas BioPharma. He is an accomplished biopharma executive with approximately 25 years of transactional and operational experience working with emerging biotechnology companies at all stages of development, from discovery through commercialization. Prior to joining Zenas, he served as Chief Operating Officer at Xilio Therapeutics, a pre-clinical oncology company, where he led the general and administrative, business development, and business operations functions. Prior to Xilio he was the General Counsel and Corporate Secretary at TESARO, where he led the global legal, compliance and government affairs functions and was a key member of the leadership team through its acquisition by GlaxoSmithKline in 2019. He previously served as Chief Corporate Counsel at Cubist Pharmaceuticals through its acquisition by Merck in 2015 and as General Counsel at two publicly traded companies, including AMAG Pharmaceuticals, where he was also the Chief Administrative Officer. He began his career as a corporate attorney at Testa Hurwitz & Thibeault.

Throughout his career, Mr. Farmer has been involved in numerous large and complex financing, business development, and M&A transactions, together approaching $20 billion in aggregate value. He received his J.D. from Boston College Law School and his B.A. in economics from Boston University.

Heidi Kempinski, MBA, Chief Operating Officer (USA)

Ms. Kempinski is the Chief Operating Officer for Zenas USA. She also serves as Senior Principal and Operating Executive at Tellus BioVentures, LLC, an early-stage life sciences investment fund, and Chief Operating Officer for Aegle Therapeutics. Previously, she served as VP of Business Operations and Strategic Alliances at GlaxoSmithKline following the acquisition of TESARO in 2019. Ms. Kempinski was part of the founding management team of TESARO where she established pharmaceutical development and manufacturing, quality, regulatory, clinical operations, and program management for the company. She also managed business development diligence processes, all global development and commercialization relationships with licensors and licensees, and collaborative discovery, clinical and diagnostic relationships.

Ms. Kempinski began her career as a molecular biologist followed by a 25+ year career in executive roles in R&D Operations and Program Management at several biopharmaceutical companies including Abraxis BioScience, Eisai, MGI PHARMA, Altus Pharmaceuticals, ZYCOS, and Transkaryotic Therapies. She received a B.S. in Microbiology and Chemistry from Quinnipiac University and an MBA with a specialty in innovation and entrepreneurship from Northeastern University.

Eric Haltom, Senior Vice President, Global Clinical Development Operations

Mr. Haltom is the Senior Vice President, Global Clinical Development Operations of Zenas BioPharma. He is an accomplished biopharma executive with 30 years of clinical research and operational experience working with emerging biotechnology companies at all stages of clinical development.  Prior to joining Zenas, he served as Senior Vice President, Clinical Operations at Deciphera Pharmaceuticals, a commercial oncology company, where he established and led the Clinical Operations and Clinical Business Operations function for 5 years. Prior to Deciphera he was the Head of Clinical Operations at Shire, where he led the global clinical operations group and was a key member of the Clinical Development leadership team.

Throughout his career, Mr. Haltom has been involved in various start up and established global organizations building comprehensive clinical operations teams. He received his B.A in business from Saint Anselm College.

Bill Gaskins, Vice President, Global Quality Assurance

Mr. Gaskins serves as Vice President, Global Quality Assurance at Zenas. Prior to joining Zenas, he served as Group Vice President of Global Quality/Operations at Boston Pharmaceuticals. Previously, Mr. Gaskins held roles of increasing responsibility at Eli Lilly over 35+ years. He began his career as an analytical chemist who transitioned into biomanufacturing and then into quality assurance oversight roles, ultimately serving as the Chorus Global Quality Head. Mr. Gaskins was a founding member of Chorus, a full-service, autonomous special force unit within Eli Lilly that specializes in proof of concept clinical development for internal and external assets.

Mr. Gaskins holds a bachelor’s degree in Chemistry and Mathematics from Indiana University.

Steve MacDonald, CPA, MBA, Vice President, Finance and Corporate Controller

Mr. MacDonald serves as Vice President, Finance and Corporate Controller at Zenas. Prior to joining Zenas, he served as Vice President of Finance & Accounting and Treasurer at Eloxx Pharmaceuticals and was the principal financial and accounting officer for this publicly traded biotech company. Prior to Eloxx, Mr. MacDonald was Senior Director, Financial Reporting at TESARO where in addition to his finance, equity accounting and treasury responsibilities, he led the assessment and accounting for multiple in-license, out-license, and collaboration arrangements and contributed to four follow-on public stock offerings, convertible note, PIPE and term loan financings totaling over $1.5 billion. He previously worked at PwC as an Audit Senior Associate and served in controller functions at Sapient Corporation and Network Engines.

Mr. MacDonald is a graduate of Williams College and obtained an MBA from Suffolk University.

Allen Poma, MD, MBA, Vice President, Clinical Development (USA)

Dr. Poma is the Vice President, Clinical Development for Zenas USA. Prior to joining Zenas, he served as Vice President of Medical Development at Ultragenyx Pharmaceutical where he was responsible for the clinical development of multiple therapeutic indications for rare disease product programs. Dr. Poma previously held roles of increasing responsibility at TESARO, AMAG Pharmaceuticals and Stryker. Prior to joining Stryker, Dr. Poma was an Assistant Professor at the Yale School of Medicine and previously Medical Director at Quinnipiac University.

Dr. Poma received his medical degree from Wake Forest School of Medicine, an MBA from Columbia Business School and a B.S. in Biology from the University of North Carolina at Chapel Hill.

Gan Wei, Ph.D., Vice President, Global Technical Operations

Dr. Wei is Vice President, Global Technical Operations at Zenas. Prior to joining Zenas, he served as Vice President, Interim Head of Technical Operations at Voyager Therapeutics. Previously, Dr. Wei was the Senior Director of Biologics Process Development at Momenta Pharmaceuticals, followed by Executive Director of Biologics Drug Substance and Analytical Sciences at TESARO. Dr. Wei has over 20 years of experience in the biopharmaceutical industry spanning biologics process development and cGMP manufacturing support, including commercialization to life cycle management.

Dr. Wei received a Ph.D. and M.S. in Chemical and Biochemical Engineering from the University of Maryland, Baltimore County, and an M.S. and B.S. in Biochemical Engineering from East China University of Science and Technology.

Keith Wilcoxen, Ph.D., Vice President, Global Non-Clinical Development

Dr. Wilcoxen serves as Vice President, Global Non-Clinical Development at Zenas. Prior to joining Zenas, he was the Vice President of Diligence and Non-Clinical Development, followed by Vice President of Translational Research at Boston Pharmaceuticals where he was a core member of the Research & Development Leadership team. Dr. Wilcoxen has more than 20 years of experience in the biopharmaceutical industry including the successful submission of multiple investigational new drug applications. He previously held roles of increasing responsibility in non-clinical drug development and discovery with TESARO, Eisai, Neurocrine Biosciences, and Pfizer.

Dr. Wilcoxen received a Ph.D. in Chemistry from Scripps Research Institute and a B.A. in Chemistry from Northwestern University.

Board of Directors

Lonnie Moulder, Founder & Executive Chair

Mr. Moulder, Founder of Zenas BioPharma, serves as our Executive Chair and is the Managing Member of Tellus BioVentures, LLC, an early-stage life sciences investment fund. Prior to establishing Tellus BioVentures, he cofounded TESARO (a fully-integrated Boston based oncology-focused biopharmaceutical company) and served as CEO and Director until its acquisition by GlaxoSmithKline in January 2019. Mr. Moulder previously served as President and CEO of Abraxis BioScience. Prior to Abraxis he served as Vice Chairman of Eisai Corporation of North America following Eisai’s acquisition of MGI PHARMA, where he served as President and CEO. This followed him serving as a member of the founding management team of a venture-stage biotech company. Mr. Moulder began as a clinical pharmacist followed by a 17-year career at predecessor companies of Sanofi, beginning with Marion Laboratories.

Mr. Moulder is a Temple University Trustee and Chair of the Trustee Committee for Research. He is a Council Member for both the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation. Mr. Moulder serves on the Board of Directors for Zai Lab, Helsinn Group and Trevena and for the Tellus BioVentures portfolio companies: Aegle Therapeutics, Dianthus Therapeutics, Interius BioTherapeutics and TamuroBio. He received a Pharmacy degree from Temple University and an MBA from The University of Chicago Booth School of Business.

Hua Mu, MD, Ph.D., President and Chief Executive Officer, Acting Chief Medical Officer

Dr. Hua Mu serves as President and Chief Executive Officer and Acting Chief Medical Officer at Zenas. Prior to joining Zenas, Dr. Mu was the co-founder of Overland Pharmaceuticals and served as Interim CEO and CMO, while also serving as Venture Partner at Hillhouse Capital. Prior to Overland, Dr. Mu served as CSO and President of R&D and later CMO of Simcere Pharmaceutical Group and President of Simcere of America Inc. Before Simcere, he was SVP and Global Head of Product Development Service and Partnership at WuXi AppTec. Prior to WuXi, he was EVP and CMO at Hutchison MediPharma in China. He previously held Medical Director and Head of Medical Affairs positions at several global pharmaceutical companies in the US, including Roche, Abraxis BioScience (Celgene/BMS), Biogen, and Genentech. With extensive experience in building and leading R&D organizations and international collaborations, Dr. Mu has a proven track record of successful development and approval of new drugs in China and around the globe. He participated in and led the development of more than 20 innovative drug candidates in multiple therapeutic areas, including three drugs approved in the US and global market, four in China, and an NDA currently under priority review in China.

Dr. Mu conducted translational and clinical research at the University of California, San Francisco and at the University of Washington Medical School before joining industry in 1999. He received his PhD in Genetic Epidemiology from the University of California at Berkeley and completed his post-doctorate training at University of California at San Francisco School of Medicine and University of Washington Medical School. Dr. Mu received his MD degree from West China University of Medical Sciences.

Ke (Kevin) Huang, Ph.D., Managing Director, WuXi Biologics HealthCare Venture

Dr. Huang is currently Managing Director at WuXi Biologics HealthCare Venture, the life sciences investment fund of WuXi Biologics. He also serves as Chief of Staff, Head of Corporate Strategy and Investment for WuXi Biologics. Previously, Dr. Huang was a biologics manufacturing scientist at Bristol-Myers Squibb. He earned a Ph.D. in Pharmaceutical Chemistry from the University of Illinois College of Pharmacy, an M.S. in Analytical Chemistry, Pharmaceutics from the University of Minnesota-Twin Cities, and a B.S. in Geochemistry, Chemistry from Peking University.

Tomas Kiselak, Managing Member, Fairmount Funds

Mr. Kiselak serves as Managing Member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount Funds, Mr. Kiselak served as a managing director at RA Capital Management LLC, based in Boston. In addition to his responsibilities at Fairmount Funds, Mr. Kiselak serves as a Director at Viridian Therapeutics, Inc., and a strategic advisor to Dianthus Therapeutics, Inc. He received his BA in Neuroscience and Economics from Amherst College.

Marietta Wu, MD, Ph.D., MBA, Managing Director, Quan Capital

Dr. Wu is Managing Director of Quan Capital, a life sciences venture fund with offices in China and the US. She is a founding member of Zai Lab (NASDAQ: ZLAB) and served as Chief Operating Officer and Director of the company prior to Quan Capital. Over the past decade, Dr. Wu has been active in cross-border ventures and value creation in the life sciences industry.  Dr. Wu is also a frequent speaker and an author on China and Taiwan life sciences topics, and a founding member of the China Healthcare Investment Conference.

Dr. Wu received her medical degree from Shanghai Jiaotong University School of Medicine (formerly Shanghai Second Medical University), a Ph.D. in Medical Sciences from Medical College of Ohio, and an MBA from the University of Michigan Ross School of Business. Dr. Wu serves on the board of Citrine, Crescendo Biologics, Innoforce, Kira Pharmaceutical, MEDx Translational Medicine and Zidan Medical.

Our Investors

long-arrow-right-regularfacebook-brandsfacebook-f-brandsinstagram-brandslinkedin-brandslinkedin-in-brandssubmit-arrowtwitter-brandstwitter-square-brandsyoutube-brands